Optimum imaging strategies for advanced prostate cancer: ASCO guideline

EJ Trabulsi, RB Rumble, H Jadvar, T Hope… - Journal of Clinical …, 2020 - ir.lib.uwo.ca
PURPOSE Provide evidence-and expert-based recommendations for optimal use of
imaging in advanced prostate cancer. Due to increases in research and utilization of novel …

The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy

S Raveenthiran, J Yaxley, T Gianduzzo, B Kua… - Prostate Cancer and …, 2019 - nature.com
Abstract Background 68Ga-PET/CT PSMA scan is being increasingly used for the staging of
biochemically recurrent disease. Early identification of recurrent disease after radiotherapy …

Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy

X Wu, H Scott, SV Carlsson, DD Sjoberg… - The …, 2019 - Wiley Online Library
Background Enhancer of zeste 2 (EZH2) promotes prostate cancer progression. We
hypothesized that increased EZH2 expression is associated with postradiotherapy …

[HTML][HTML] Systematic review & meta-analysis of positron emission tomography/computed tomography and bone scan in the diagnosis of prostate lesions

J Wang, Y Han, L Lin, L Zhang, J Li… - … Andrology and Urology, 2021 - ncbi.nlm.nih.gov
Background To date, the results of studies into the effectiveness of positron emission
tomography (PET) combined with computed tomography (CT) and bone scan (BS) in the …

[HTML][HTML] Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical …

A Natarajan, A Agrawal, V Murthy… - World journal of …, 2019 - thieme-connect.com
Gallium-68 labeled prostate-specific membrane antigen (Ga-68 PSMA) ligand (HBED-CC) is
a novel tracer used for prostate cancer imaging. The aim of the study was to investigate the …

Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen …

L Evangelista, L Cuppari, A Guttilla… - Nuclear Medicine …, 2018 - journals.lww.com
Purpose The aim of this study was to assess the ability of fluorine-18-fluorocholine (18 F-
FCH) PET/computed tomography (CT) to detect oligometastatic disease (OMD) in patients …

Reply: Comparison of 68Ga-PSMA-11 and 18F-fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence: prospective trial is on its way

J Calais, WP Fendler, K Herrmann… - Journal of Nuclear …, 2018 - Soc Nuclear Med
REPLY: We thank Bela Denes and Peter Gardiner from Blue-Earth Diagnostics, Inc., for their
interest in our case series (1) and their relevant letter. BlueEarth Diagnostics, Inc., showed …

[HTML][HTML] Impact of the 68Ga Prostate-Specific Membrane Antigen (68Ga-PSMA) PET/CT on the Management of Prostate Cancer

S Gurunath, S Salunke… - Journal of Exploratory …, 2020 - xiahepublishing.com
This review discusses the efficiency and sensitivity of 68 Ga-labelled prostate-specific
membrane antigen (PSMA) positron emission tomography (PET)/computed tomography …

[HTML][HTML] The diagnostic value of PET/CT imaging with the 68Ga-labeled PSMA-ligand in the follow up assessment of prostate cancer after therapy

TAAEH Hassan, MS Elazab - Egyptian Journal of Radiology and Nuclear …, 2020 - Springer
Background The aim of this study is to investigate the role of PET/CT imaging with the 68Ga-
labeled PSMA-ligand in the follow up assessment of post-operative and post-therapeutic …

Evaluation of PET image for fluorine-18 and gallium-68 using phantom in PET/CT

SH Yoon - Journal of radiological science and technology, 2018 - koreascience.kr
The purpose of this study is to compare PET imaging performance with Fluorine-18 ($^{18} F
$) and Gallium-68 ($^{68} Ga $) for influence of physical properties of PET tracer …